Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Artificial Heart Stocks Thoratec & Heartware Vie for Your Love

Both artificial heart developers THOR and HTWR have had a volatile run lately. But in this feud, perhaps only one device maker can win Wall Street's affections.

Could Legalized Pot Give Big Pharma a Much-Needed Boost?

Medical marijuana is big business where it's legalized, and if major pharmaceutical companies could get a share of the market they could see a big boost.

Vertex vs. Merck in Hepatitis Drug Title Fight

All that's at stake is a $10 billion market.

Overseas Drug Test Trend May Cost AstraZeneca

The company's promising heart drug may face delays

Tenet Shares Are Off Life Support, For Now

Until the government finds a way to keep Medicare solvent well beyond projections, investors might want to proceed with caution on Tenet.